Advertisement

Topics

Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity

09:10 EDT 13 Sep 2018 | NIH

Natural killer T cells (NKT) are a unique lymphocyte population that has T-cell and NK cell functional properties in order to rapidly elicit an immune response.  alpha-galactosylceramide (alpha-GalCer) is a potent NKT stimulator and induces of IFN-gamma release to promote immunity against tumors and infectious agents.  Humans have natural antibodies against alpha-galactose, which may be one of the reasons why the human clinical trials of alpha-GalCer or KRN7000 were not very successful.

Beta-ManCer is a new class of NKT agonist that induces immune responses alone, through nitric oxide and TNF-alpha-dependent mechanisms, or synergistically with alpha-GalCer to enhance alpha-GalCer''s efficacy.  Since beta-ManCer does not have alpha-galactose, which can be neutralized by natural antibodies, patients could be treated with multiple doses without negative side effects associated with the loss of IFN-gamma production.  Hence, beta-ManCer is a promising anti-cancer treatment either alone or in combinatorial therapies with alpha-GalCer to selectively induce immune responses.

IC: 
NCI
NIH Ref. No.: 
E-034-2010
Advantages: 
  • Induces tumor immunity through a novel mechanism
  • Decreased possibility of neutralization by natural antibodies
  • Synergize with alpha-GalCer
Applications: 
  • Cancer therapeutics
  • Potent stimulator of NKT activity
Development Status: 

Discovery (Lead Identification)

Updated On: 
Jul 19, 2018
Provider Classifications: 
Publications: 
Patent Application: 
61/313,508
Patent Authority: 
U.S. Provisional
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
Inventor Lab URL: 
https://ccr.cancer.gov/Vaccine-Branch/masaki-terabe
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Pat Filing Date: 
2010-03-12
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing only

E Number Only: 
E-034-2010
Inventor First Name: 
Masaki
Ira
Inventor Last Name: 
Terabe
Pastan

Original Article: Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity

NEXT ARTICLE

More From BioPortfolio on "Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...